Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Reliance Life Sciences Pvt. Ltd. Snapshot | 5 | 1 |
Reliance Life Sciences Pvt. Ltd. Overview | 5 | 1 |
Key Information | 5 | 1 |
Key Facts | 5 | 1 |
Reliance Life Sciences Pvt. Ltd. Research and Development Overview | 6 | 2 |
Key Therapeutic Areas | 6 | 2 |
Reliance Life Sciences Pvt. Ltd. Pipeline Review | 8 | 4 |
Pipeline Products by Stage of Development | 8 | 1 |
Pipeline Products Monotherapy | 9 | 1 |
Pipeline Products Out-Licensed Products | 10 | 1 |
Out-Licensed Products/Combination Treatment Modalities | 11 | 1 |
Reliance Life Sciences Pvt. Ltd. Pipeline Products Glance | 12 | 5 |
Reliance Life Sciences Pvt. Ltd. Late Stage Pipeline Products | 12 | 1 |
Phase III Products/Combination Treatment Modalities | 12 | 1 |
Reliance Life Sciences Pvt. Ltd. Clinical Stage Pipeline Products | 13 | 1 |
Phase II Products/Combination Treatment Modalities | 13 | 1 |
Reliance Life Sciences Pvt. Ltd. Early Stage Pipeline Products | 14 | 1 |
Preclinical Products/Combination Treatment Modalities | 14 | 1 |
Discovery Products/Combination Treatment Modalities | 15 | 1 |
Reliance Life Sciences Pvt. Ltd. - Unknown Stage Pipeline Products | 16 | 1 |
Unknown Products/Combination Treatment Modalities | 16 | 1 |
Reliance Life Sciences Pvt. Ltd. Drug Profiles | 17 | 10 |
cetuximab biosimilar | 17 | 1 |
Product Description | 17 | 1 |
Mechanism of Action | 17 | 1 |
R&D Progress | 17 | 1 |
darbepoetin alfa | 18 | 1 |
Product Description | 18 | 1 |
Mechanism of Action | 18 | 1 |
R&D Progress | 18 | 1 |
pegfilgrastim | 19 | 1 |
Product Description | 19 | 1 |
Mechanism of Action | 19 | 1 |
R&D Progress | 19 | 1 |
etanercept biosimilar | 20 | 1 |
Product Description | 20 | 1 |
Mechanism of Action | 20 | 1 |
R&D Progress | 20 | 1 |
Antisense RNAi Oligonucleotides for Undisclosed Indications | 21 | 1 |
Product Description | 21 | 1 |
Mechanism of Action | 21 | 1 |
R&D Progress | 21 | 1 |
RSCL-0520 | 22 | 1 |
Product Description | 22 | 1 |
Mechanism of Action | 22 | 1 |
R&D Progress | 22 | 1 |
somatropin biosimilar | 23 | 1 |
Product Description | 23 | 1 |
Mechanism of Action | 23 | 1 |
R&D Progress | 23 | 1 |
Monoclonal Antibodies for Oncology and Inflammation | 24 | 1 |
Product Description | 24 | 1 |
Mechanism of Action | 24 | 1 |
R&D Progress | 24 | 1 |
RSCL-0521 | 25 | 1 |
Product Description | 25 | 1 |
Mechanism of Action | 25 | 1 |
R&D Progress | 25 | 1 |
NeuroRel | 26 | 1 |
Product Description | 26 | 1 |
Mechanism of Action | 26 | 1 |
R&D Progress | 26 | 1 |
Reliance Life Sciences Pvt. Ltd. Pipeline Analysis | 27 | 4 |
Reliance Life Sciences Pvt. Ltd. Pipeline Products by Target | 27 | 1 |
Reliance Life Sciences Pvt. Ltd. Pipeline Products by Route of Administration | 28 | 1 |
Reliance Life Sciences Pvt. Ltd. Pipeline Products by Molecule Type | 29 | 1 |
Reliance Life Sciences Pvt. Ltd. Pipeline Products by Mechanism of Action | 30 | 1 |
Reliance Life Sciences Pvt. Ltd. - Dormant Projects | 31 | 1 |
Reliance Life Sciences Pvt. Ltd. Locations And Subsidiaries | 32 | 2 |
Head Office | 32 | 1 |
Other Locations &Subsidiaries | 32 | 2 |
Appendix | 34 | 2 |
Methodology | 34 | 1 |
Coverage | 34 | 1 |
Secondary Research | 34 | 1 |
Primary Research | 34 | 1 |
Expert Panel Validation | 34 | 1 |
Contact Us | 34 | 1 |
Disclaimer | 35 | 1 |